GLP-1 Receptor Agonists: Comprehensive Overview
What is GLP-1?
Glucagon-like peptide-1 (GLP-1) is a 30-amino acid incretin hormone secreted by intestinal L-cells in response to nutrient intake that functions as part of the ileal brake mechanism, signaling nutritional abundance and regulating glucose homeostasis, appetite, and gastric motility 1.
Mechanism of Action
GLP-1 receptor agonists work through multiple pathways:
Pancreatic Effects:
- Enhance glucose-dependent insulin secretion from beta cells
- Suppress glucagon release (both glucose-dependent, minimizing hypoglycemia risk) 2
- Promote pancreatic beta-cell growth 3
Central Nervous System Effects:
- Activate GLP-1 receptors in the hypothalamus (arcuate nucleus) and brainstem (area postrema, nucleus tractus solitarius) 4
- Suppress appetite and increase satiety
- Reduce food intake through vagal afferent pathways and direct CNS receptor activation 5
Gastrointestinal Effects:
- Delay gastric emptying by inhibiting vagal activity and reducing phasic gastric contractions 4
- Reduce gastric acid secretion
- Increase fasting and postprandial gastric volumes 4
Cardiovascular and Renal Effects:
- Improve myocardial substrate utilization
- Provide anti-inflammatory and anti-atherosclerotic effects
- Reduce systemic and pulmonary vascular resistance
- Improve lipid profiles 4
Clinical Indications
Type 2 Diabetes Management
For patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, GLP-1 receptor agonists with proven cardiovascular benefit (liraglutide, semaglutide, dulaglutide) are recommended as first-line injectable therapy, independent of baseline HbA1c 6.
Specific Recommendations by Patient Profile:
- Established ASCVD (prior MI, stroke, revascularization): GLP-1 RAs have the strongest evidence for MACE reduction 7
- High CV risk without established disease: Consider in patients ≥55 years with arterial stenosis >50%, LVH, eGFR <60 mL/min/1.73m², or albuminuria 7
- Chronic kidney disease: Use if SGLT2 inhibitors are not tolerated or contraindicated; effective down to eGFR ≥20 mL/min/1.73m² 8
- Heart failure with reduced ejection fraction: SGLT2 inhibitors preferred, but GLP-1 RAs are alternative 6
Obesity Management
Liraglutide 3 mg daily (FDA approved 2014) and semaglutide 2.4 mg weekly (FDA approved 2021) are indicated for weight management in patients with BMI ≥30 or BMI ≥27 with weight-related comorbidities 4.
Weight Loss Efficacy:
- Liraglutide: Mean 8% weight loss at 56 weeks 3
- Semaglutide: Mean 14.9-16% weight loss at 68 weeks 3
- Greater efficacy in non-diabetic patients (6.1-17.4%) versus diabetic patients (4-6.2%) 4
Dosing Recommendations
Available Formulations 8
Short-Acting (Daily):
- Liraglutide: Start 0.6 mg daily, increase to 1.2-1.8 mg after 1 week (diabetes); 3 mg daily for obesity
- Lixisenatide: Start 10 mg daily, increase to 20 mg on day 15
- Exenatide: Start 5 mg twice daily, increase to 10 mg after 1 month
Long-Acting (Weekly):
- Semaglutide: Start 0.25 mg weekly, titrate to 0.5-1 mg (diabetes); 2.4 mg for obesity
- Dulaglutide: Start 0.75 mg weekly, increase to 1.5 mg if needed
- Exenatide XR: 2 mg once weekly
Critical Dosing Principle: Start at low doses and titrate slowly to minimize gastrointestinal side effects 4.
Renal Dosing
No dose adjustment required for most GLP-1 RAs down to eGFR ≥20 mL/min/1.73m² 8. This represents a significant advantage over many other diabetes medications.
Contraindications and Precautions
Absolute Contraindications
- Active gastroparesis 4
- Personal or family history of medullary thyroid carcinoma 9
- Multiple endocrine neoplasia syndrome type 2 9
- Pregnancy (not approved for use)
Relative Contraindications and High-Risk Situations
Active Eating Disorders:
- Avoid in active anorexia nervosa, atypical anorexia nervosa, and bulimia nervosa with marked dietary restraint or significant weight suppression 10
- Proceed cautiously with past history of these disorders
- Screen for current and historical eating disorders before initiation using validated instruments 10
History of Pancreatitis:
- Use with caution; insufficient data for causality but case reports exist 9
- American Association of Clinical Endocrinologists recommends caution in patients with prior pancreatitis 4
Diabetic Retinopathy:
- Semaglutide associated with increased retinopathy complications (HR 1.76) in SUSTAIN 6, particularly with rapid glycemic improvement 6
- Monitor closely in patients with baseline retinopathy
Foot Ulcers/Amputation Risk:
- While primarily a concern with SGLT2 inhibitors, careful shared decision-making needed 7
Adverse Effects and Management
Common Gastrointestinal Effects (Most Frequent)
Nausea (25%), vomiting, and diarrhea (up to 10%) are dose-dependent and more common with short-acting agents 9, 4.
Management Strategies 4:
- Start at low dose and titrate slowly
- Eat smaller meals
- Drink plenty of water
- Increase dietary fiber
- Eat slowly and stop when full
- Avoid high-fat or spicy foods
- Moderate alcohol and carbonated drinks
- Effects typically diminish over time with tolerance development
Serious Adverse Effects
Delayed Gastric Emptying:
- Persists even with tachyphylaxis to other effects 4
- Critical perioperative concern: Increased aspiration risk with retained gastric contents 4
- Scintigraphy demonstrates delayed emptying on exenatide, liraglutide, and semaglutide 4
Gallbladder Disorders:
Cardiac Effects:
- Potential arrhythmia/tachycardia 4
- If symptomatic, monitor and consider beta-blockers
Acute Kidney Injury:
- Risk of dehydration and orthostatic hypotension
- Use caution with concurrent diuretics, ACE inhibitors, or ARBs 6
Cardiovascular and Renal Benefits
Proven Cardiovascular Outcomes
Liraglutide (LEADER trial):
- 13% reduction in MACE (CV death, non-fatal MI, stroke): RR 0.87 (95% CI 0.78-0.97) 4
- Reduced cardiovascular and all-cause mortality 9
Semaglutide (SUSTAIN 6):
- 26% reduction in MACE: RR 0.74 (95% CI 0.58-0.95) 4
- Benefits extend to non-diabetic patients with pre-existing CVD 4
Dulaglutide (REWIND):
- Lower incidence of MACE-3 regardless of baseline HbA1c 9
Renal Benefits
Semaglutide (FLOW trial):
- Significantly reduced risk of major kidney disease events in patients with T2DM and CKD 9
- Prevention of new-onset macroalbuminuria
- Reduced urinary albumin excretion
- Slowed eGFR decline 9
Note: SGLT2 inhibitors remain preferred for delaying CKD progression 9.
Special Populations and Considerations
Older Adults
- Approximately 40% have obesity and 29% have T2DM 11
- Sarcopenia risk: Weight loss efforts require cautious approaches to preserve muscle mass
- Monitor for polypharmacy interactions
- Consider increased comorbidity burden 11
Perioperative Management
Critical Safety Concern: Emerging case reports of aspiration/regurgitation during general anesthesia despite fasting 4.
Current Evidence:
- Delayed gastric emptying persists even with chronic use 4
- Tachyphylaxis to vagal suppression occurs, but gastric emptying remains delayed 4
- Insufficient evidence for minimum cessation period 4
Practical Approach:
- Consider gastric ultrasound assessment preoperatively
- Discuss aspiration risk mitigation strategies with anesthesia
- Balance against risk of worsening glycemic control with prolonged cessation 4
Long-Term Use and Treatment Cessation
Weight regain is significant after discontinuation:
- 11.6% weight regain after 52 weeks post-treatment (STEP 1) 3
- 6.9% weight regain when transitioned to placebo (STEP 4) 3
Therefore, GLP-1 RAs require lifelong use for sustained benefit 3. Any prescription should include a plan to mitigate adverse effects of treatment termination 1.
Clinical Pearls and Pitfalls
Maximizing Efficacy
- Combine with lifestyle modifications: Reduced calorie intake and exercise enhance response 9
- Recognize responders vs. non-responders: Biological factors likely contribute to variable response 9
- Semaglutide has highest efficacy for both glycemic control and weight loss compared to other GLP-1 RAs 9, 6
Common Pitfalls to Avoid
- Rapid dose escalation: Increases GI side effects and discontinuation rates
- Inadequate patient education: Counsel on expected side effects, dietary modifications, and need for long-term use
- Ignoring eating disorder screening: Screen before initiation and monitor routinely 10
- Combining with insulin/sulfonylureas without dose adjustment: Increases hypoglycemia risk 6
- Prescribing without lifestyle modification plan: Reduces efficacy and increases side effects 1
Cost-Effectiveness
GLP-1 RAs are cost-effective due to reduced healthcare costs from fewer hospitalizations and lower mortality rates 12, though upfront medication costs remain a barrier to access.